According to Ionis Pharmaceuticals Inc’s most recent Statement Of Changes In Beneficial Ownership – Form 4 filing with the SEC dated Nov 25 07:02 PM, company EVP, Finance & CFO, Hougen Elizabeth L disclosed selling 19,000 shares at a cost of $50.11. At the time of this transaction (Nov 23), this trade was worth $952,090 […]
According to Travere Therapeutics, Inc.’s most recent Statement Of Changes In Beneficial Ownership – Form 4 filing with the SEC dated Nov 25 07:00 PM, company Chief Financial Officer, Clague Laura disclosed selling 3,750 shares at a cost of $22.72. At the time of this transaction (Nov 25), this trade was worth $85,200 in total. […]
According to Travere Therapeutics, Inc.’s most recent Statement Of Changes In Beneficial Ownership – Form 4 filing with the SEC dated Nov 25 07:00 PM, company Chief Financial Officer, Clague Laura disclosed selling 3,750 shares at a cost of $23.86. At the time of this transaction (Nov 24), this trade was worth $89,475 in total. […]
According to Halozyme Therapeutics, Inc.’s most recent Statement Of Changes In Beneficial Ownership – Form 4 filing with the SEC dated Nov 25 06:59 PM, company Director, Henderson Jeffrey William disclosed selling 24,498 shares at a cost of $40.08. At the time of this transaction (Nov 25), this trade was worth $981,757 in total. As […]
According to Ionis Pharmaceuticals Inc’s most recent Statement Of Changes In Beneficial Ownership – Form 4 filing with the SEC dated Nov 25 06:58 PM, company EVP, Development, Geary Richard S disclosed selling 2,380 shares at a cost of $50.83. At the time of this transaction (Nov 24), this trade was worth $120,975 in total. […]
According to Ionis Pharmaceuticals Inc’s most recent Statement Of Changes In Beneficial Ownership – Form 4 filing with the SEC dated Nov 25 06:58 PM, company EVP, Development, Geary Richard S disclosed selling 10,700 shares at a cost of $50.11. At the time of this transaction (Nov 23), this trade was worth $536,177 in total. […]
According to Halozyme Therapeutics, Inc.’s most recent Statement Of Changes In Beneficial Ownership – Form 4 filing with the SEC dated Nov 25 06:57 PM, company Director, Daly James M disclosed selling 10,363 shares at a cost of $40.41. At the time of this transaction (Nov 25), this trade was worth $418,800 in total. As […]
According to Ionis Pharmaceuticals Inc’s most recent Statement Of Changes In Beneficial Ownership – Form 4 filing with the SEC dated Nov 25 06:56 PM, company Director, Parshall B Lynne disclosed selling 710 shares at a cost of $50.82. At the time of this transaction (Nov 24), this trade was worth $36,082 in total. As […]
According to Ionis Pharmaceuticals Inc’s most recent Statement Of Changes In Beneficial Ownership – Form 4 filing with the SEC dated Nov 25 06:56 PM, company Director, Parshall B Lynne disclosed selling 3,200 shares at a cost of $50.12. At the time of this transaction (Nov 23), this trade was worth $160,384 in total. As […]
According to Halozyme Therapeutics, Inc.’s most recent Statement Of Changes In Beneficial Ownership – Form 4 filing with the SEC dated Nov 25 06:56 PM, company President and CEO, Torley Helen disclosed selling 50,000 shares at a cost of $40.73. At the time of this transaction (Nov 25), this trade was worth $2,036,568 in total. […]
PayPal Withdrawing Support For Kindle Fire, BlackBerry And Windows Phone
Revival Of Nashville Discussed
Brawl Erupts After Jose Bautista Downed By Rougned Odor Punch
VR Tour Offered Three Decades After Chernobyl Disaster
Kyle Busch Sweeps NASCAR Events At Martinsville
Halle Berry Enters The Social Media World
